Communiqués Arch Biopartners Inc. Toronto S.E.

Actions

ARCH

CA03938C1041

Marché Fermé - Toronto S.E. Autres places de cotation 22:16:31 07/06/2024			Varia. 5j.	Varia. 1 janv.
1,75 ^CAD	+4,79 %		+4,79 %	+18,24 %

31/05	Arch Biopartners Inc. publie ses résultats pour le deuxième trimestre et le semestre clos le 31 mars 2024	CI
16/04	Arch Biopartners Inc. Michael's Hospital se joint à l'essai de phase II du peptide LSALT ciblant les lésions rénales aiguës associées à la chirurgie cardiaque	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Arch Biopartners Inc. - St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	17/04	AQ
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	16/04	AQ
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	03/04	AQ
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	02/04	AQ
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2	18/03	AQ
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	15/03	AQ
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	07/03	AQ
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury	27/02	AQ
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	10/01	AQ
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	03/01	AQ
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide	21/12	AQ
Grant of Options to Directors and Officers	18/12	AQ
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide	13/12	AQ
Shares for Interest Debt Settlement	24/10/23	AQ
Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide	22/09/23	AQ
Arch Biopartners : 2023 Q3 Interim Financial Statements	30/08/23	PU
Arch Biopartners Engages Independent Trading Group as Market Maker	01/08/23	AQ
Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial	27/06/23	AQ
Arch Biopartners : 2023 Q2 Interim Financial Statements	31/05/23	PU
Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide	18/04/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Arch Biopartners Inc. Toronto S.E.

Actions

ARCH

CA03938C1041

Communiqués

Filtres